Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
about
Inhibition of the STAT3 signaling pathway is involved in the antitumor activity of cepharanthine in SaOS2 cells.Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.ABCG2: a perspective.Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine.ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Identifying a Small Molecule Blocking Antigen Presentation in Autoimmune Thyroiditis.A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line.Reversing multidrug resistance by tyrosine kinase inhibitorsABCG2: the key to chemoresistance in cancer stem cells?Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia.
P2860
Q33567034-CEE3B0F4-ED64-4B4C-ACDB-302191692AF4Q33878636-2A296441-D7B4-4FC6-B6C8-ECD4011FF8FAQ35016817-D1878C1C-53F4-4C24-A6E3-1289F755981BQ35102675-B13E2807-FF5E-49F6-8FB2-F7E2B2E968E4Q35171274-7DB01001-A428-4E1A-A592-B1243E6F419CQ35878274-A7FE45C5-911D-401D-AAFF-8B2DB94042B6Q35991845-7D66F7DF-9B9E-49ED-94FF-B036D0809EF6Q37183670-B1054240-DFA3-4185-8615-4A9FE1085EC2Q37587219-250A5B47-98B8-4C64-9EB6-34EADCD11C50Q37853578-E2D4FFD4-2F0D-450E-8258-0542A9BA3C09Q39440567-1E8D8FF7-429B-4A80-B916-2CB04C5E9E89Q39805970-DCE16DE7-54CC-4A15-A0AB-9DC0717CCF32Q46586986-87E977C1-3CA6-4F1D-8447-30CE57755A51
P2860
Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
@en
Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
@nl
type
label
Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
@en
Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
@nl
prefLabel
Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
@en
Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
@nl
P2093
P2860
P1433
P1476
Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
@en
P2093
Hideo Takamatsu
Misako Haraguchi
Motoi Mukai
Motomasa Kobayashi
Shin-Ichi Akiyama
Shunji Aoki
Tatsuhiko Furukawa
Tomoyuki Sumizawa
Xiao-Fang Che
Xiao-Qin Ren
P2860
P304
P356
10.1111/J.1349-7006.2003.TB01482.X
P577
2003-06-01T00:00:00Z